• We offer tailored partnerships to support and transform drug discovery.

    Every collaboration is a bespoke arrangement, meticulously designed to discover new compounds and targets in patient relevant disease models.

  • MIMETAS offers flexible fee-for-service solutions for therapy prioritization, optimization, and de-risking of compounds.

    As an extension of your team, MIMETAS provides the expertise and resources needed for effective research and development.

  • Our OrganoReady program is made for you when you need optimized assays for investigational toxicology.

    We guarantee OrganoReady performance according to specifications, in a fast and convenient sales transaction with a clear fee structure.

  • Giving you some food for thought. Read our blogs to learn more about 3D tissue culture, research backgrounds, developments, and its future outlook.
  • Get inspired by research done by our scientists, partners, and customers around the globe.

  • Learn about our mission, vision, the history of the company, and find out what we mean with MIMETAS-do.
open menu icon close menu icon
EN

MIMETAS Launches OrganoPlate UniFlow Technology

Leiden, January 27, 2025 — Leiden, Netherlands, January 27, 2025 — MIMETAS, a global leader in human disease modeling, has launched OrganoPlate UniFlow (UF), the first commercially available unidirectional, gravity-driven pumpless flow system for drug discovery and disease research. This innovative platform debuts as a key addition to MIMETAS’ service portfolio.


OrganoPlate UF addresses challenges in traditional flow systems by enabling physiologically accurate tissue models that replicate natural biological conditions. With unidirectional, gravity-driven flow, this system eliminates the need for external pumps, simplifying operation while enhancing model accuracy. Supporting up to 512 chips in a single setup, the technology is ideal for rigorous scientific studies and large-scale screening, accelerating research without compromising biological relevance.

Key Features of OrganoPlate UF Technology:

  • Unidirectional flow: Improves modeling of vasculature for studies in cardiovascular, oncological, and immunological research.
  • Pump-free, gravity-driven design: Simplifies operations while mimicking natural flow conditions.
  • Scalable and compatible: Operates seamlessly with standard liquid handling and imaging equipment, enabling high-throughput analysis of hundreds or thousands of tissue models.
  • Stable, long-term culture: Supports extended culture of complex tissues for chronic disease and therapeutic studies.


“The MIMETAS OrganoPlate has led the field in microphysiological cell culture for over 12 years,” said Bas Trietsch, MIMETAS co-founder. “With UniFlow, we’ve achieved unidirectional flow that mimics blood circulation while maintaining the ease of use, compatibility, and throughput that make our technology exceptional.”


OrganoPlate UF is already integrated into MIMETAS’ liver, lung, brain, vasculature, and tumor models and is used to study immunological, cardiovascular, and metabolic diseases, as well as cancer. This platform is now available as part of MIMETAS’ service offerings.

Go to original press release Learn about OrganoPlate UF

Cookies

May we use cookies?
Hi there! Thanks for visiting our website. We use cookies to keep track of our website statistics to optimize the user experience. We also use cookies for marketing purposes. You can set your preferences by selecting the options below. Terms of Use & Privacy Policy
Accept all
Accept selected
Decline all